Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentiis M, Fabi A, Rimanti A, Michelotti A, Mansutti M, Russo A, Montemurro F, Frassoldati A, Durando A, Gori S, Turletti A, Tamberi S, Urracci Y, Fregatti P, Razeti MG, Caputo R, De Angelis C, Sanna V, Gasparini E, Agostinetto E, de Azambuja E, Poggio F, Boni L, Del Mastro L. Lambertini M, et al. Among authors: del mastro l. EClinicalMedicine. 2023 May 12;59:101931. doi: 10.1016/j.eclinm.2023.101931. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37256095 Free PMC article.
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C. Bianco AR, et al. Among authors: del mastro l. Ann N Y Acad Sci. 1993 Nov 30;698:330-8. doi: 10.1111/j.1749-6632.1993.tb17223.x. Ann N Y Acad Sci. 1993. PMID: 8279772 Clinical Trial. No abstract available.
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L. Venturini M, et al. Among authors: del mastro l. Breast Cancer Res Treat. 2006 Jan;95(1):45-53. doi: 10.1007/s10549-005-9030-x. Breast Cancer Res Treat. 2006. PMID: 16267615 Clinical Trial.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group.
Del Mastro L, Dozin B, Aitini E, Catzeddu T, Baldini E, Contu A, Durando A, Danese S, Cavazzini G, Canavese G, Bruzzi P, Pronzato P, Venturini M; GONO-MIG Group. Del Mastro L, et al. Ann Oncol. 2008 Feb;19(2):299-307. doi: 10.1093/annonc/mdm475. Epub 2007 Oct 17. Ann Oncol. 2008. PMID: 17947224 Free article.
Aromatase inhibitors as adjuvant therapy for breast cancer.
Montemurro F, Aglietta M, Del Mastro L. Montemurro F, et al. Among authors: del mastro l. J Clin Oncol. 2009 May 20;27(15):2566-7. doi: 10.1200/JCO.2009.22.2695. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332706 No abstract available.
340 results